891 results on '"Gianni, Luca"'
Search Results
152. Signorini’s method for live loads and second-order effects
153. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
154. Treatment of HER2-positive breast cancer: current status and future perspectives
155. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
156. Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial.
157. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
158. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
159. Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC)
160. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
161. Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis
162. Abstract P4-14-01: Modulation of tumor infiltrating lymphocytes (TILs) by palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ patients (pts) enrolled in the Michelangelo NA-PHER2 trial
163. Abstract P5-06-21: Prognostic and predictive value of PML in the ETNA study and the TCGA
164. Abstract PD5-05: Clinical implication of tumor infiltrating lymphocytes (TILs) in the ETNA study
165. Abstract P4-05-09: Molecular differences between high and low tumor mutational burden (TMB) across breast cancer (BC) subtypes
166. Anthracycline Cardiotoxicity
167. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo
168. Triple-negative breast cancer: disease entity or title of convenience?
169. New agents for the treatment of breast cancer
170. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours
171. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
172. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl- l-carnitine
173. Anthracyclines
174. The cost of life: should it matter to doctors?
175. Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer
176. Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
177. Future options with trastuzumab for primary systemic and adjuvant therapy
178. Autoimmunity and benefit from Trastuzumab treatment in breast cancer: results from the HERA trial
179. Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial
180. Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer
181. International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations
182. Is there room for another HER2-targeting drug?
183. Symptomatic and neurophysiological response of paclitaxel and/or cisplatin neuropathy to oral acetyl-L- carnitine (ALCAR)
184. Phase II study of salvage ET-743 given as 3-hr infusion in ovarian cancer (OC) patients
185. Relationship between concentrations of trastuzumab and shed HER2 extracellular domain (ECD): A meta-analysis
186. Phase I study of the oral gimatecan camptothecin given by three schedules of different duration
187. How should we integrate Herceptin?
188. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
189. Mechanism-Based Pharmacokinetic Model for Paclitaxel
190. Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer
191. Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables
192. Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation
193. PACLITAXEL, CISPLATIN, GEMCITABINE (TPG) THIRD LINE THERAPY IN METASTATIC GERM CELL TUMORS (GCT) OF THE TESTIS.
194. Prolonged primary chemotherapy (PC) with doxorubicin (A) plus paclitaxel (T) followed by weekly paclitaxel (AT&T) in women with inoperable locally advanced breast cancer (LABC).
195. Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
196. Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
197. Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.
198. Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.
199. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
200. PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.